Comparison
Armodafinil vs Clomiphene
Side-by-side of Armodafinil and Clomiphene. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Armodafinil
Armodafinil is the R-enantiomer sold as Nuvigil. Half-life 10-15 h, 150 mg standard dose, narcolepsy and shift-work approvals, Schedule IV.
Clomiphene
Clomiphene citrate raises LH/FSH and endogenous testosterone in men. SERM TRT alternative, 25 to 50 mg, fertility preserved, visual side effects flagged.
Effects at a glance
Armodafinil
- •FDA approved in 2007 for narcolepsy, shift-work sleep disorder, and OSA residual sleepiness
- •R-enantiomer of modafinil; 150 mg armodafinil is roughly equivalent to 200 mg modafinil
- •Schedule IV controlled in the US; prescription-only globally
- •Longer terminal half-life of about 15 hours produces extended late-day wakefulness coverage
- •Same CYP3A4 induction as modafinil; reduces hormonal contraceptive efficacy
- •Side-effect profile and dermatologic risk warnings mirror modafinil
Clomiphene
- •SERM that blocks estrogen-receptor negative feedback at the hypothalamus, raising LH and FSH
- •FDA approved 1967 for ovulation induction in anovulatory women at 50 to 100 mg cycle days 5 to 9
- •Off-label in men at 12.5 to 25 mg daily raises endogenous testosterone while preserving fertility
- •Enclomiphene (trans-isomer) is preferred for male use; cleaner PK and less estrogenic side effect burden
- •Visual disturbances occur in ~1 to 2% of users; persistent symptoms warrant immediate cessation
- •Letrozole has displaced clomiphene as first-line ovulation induction in PCOS (Legro 2014)
Side-by-side
| Attribute | Armodafinil | Clomiphene |
|---|---|---|
| Category | pharmaceutical | pharmaceutical |
| Also known as | Nuvigil, R-modafinil, (R)-(-)-modafinil | Clomid, clomiphene citrate, Serophene, enclomiphene |
| Half-life (hr) ↗ | 15 | 168 |
| Typical dose (mg) ↗ | 150 | 25 |
| Dosing frequency | daily, morning | 5-day pulse cycle days 5 to 9 (women); daily or every other day (men, off-label) |
| Routes | oral | oral |
| Onset (hr) | 1 | 6 |
| Peak (hr) | 3 | 7 |
| Molecular weight | 273.35 | 405.96 |
| Molecular formula | C15H15NO2S | C26H28ClNO |
| Mechanism | Weak dopamine reuptake inhibition plus downstream activation of histaminergic, noradrenergic, and orexinergic wake systems; R-enantiomer of modafinil with longer half-life. | Selective estrogen receptor modulator that antagonizes estrogen at the hypothalamus and pituitary, increasing GnRH and gonadotropin output, which drives gonadal steroidogenesis. |
| Legal status | Schedule IV (US); prescription-only globally; not a supplement | Prescription only (FDA approved for ovulation induction; off-label in men) |
| WADA status | banned | banned |
| DEA / Rx | Schedule IV | Rx only (not a controlled substance) |
| Pregnancy | Not recommended | Category X; contraindicated in pregnancy |
| CAS | 112111-43-0 | 911-45-5 |
| PubChem CID | 9148206 | 1548953 |
| Wikidata | Q4791953 | Q416785 |
Safety profile
Armodafinil
Common side effects
- headache
- nausea
- dizziness
- anxiety
- insomnia (with later-day dosing)
- dry mouth
- mild blood pressure elevation
Contraindications
- recent myocardial infarction
- unstable angina
- left ventricular hypertrophy
- significant arrhythmia
- history of Stevens-Johnson syndrome
- psychotic disorders
- pregnancy
- concurrent MAOI use
Interactions
- hormonal contraceptives: CYP3A4 induction reduces contraceptive efficacy; use barrier method(major)
- cyclosporine: reduced cyclosporine levels via CYP3A4 induction(major)
- warfarin: CYP2C9 inhibition raises INR(moderate)
- phenytoin: CYP2C19 inhibition raises phenytoin levels(moderate)
- MAOIs: potential hypertensive reaction(major)
- classical stimulants: additive cardiovascular and sleep-disruption effects(moderate)
Clomiphene
Common side effects
- hot flushes
- mood changes
- abdominal discomfort
- breast tenderness
- visual disturbances (rare)
- headache
Contraindications
- pregnancy
- active liver disease
- ovarian cysts (not PCOS-related)
- uncontrolled thyroid or adrenal disorder
- abnormal uterine bleeding of undetermined origin
- hormone-sensitive cancer
Interactions
- tamoxifen: competing SERM activity; not used together(moderate)
- ospemifene: competing SERM activity(moderate)
- anastrozole: additive estrogen reduction; sometimes combined in male protocols(minor)
- TRT (exogenous testosterone): TRT suppresses HPT axis that clomiphene targets; do not combine(moderate)
Which Should You Take?
Armodafinil comes out ahead for most readers on the criteria we weight: 3 catalogued goals, controlled substance, oral dosing, with a Tier-A outcome catalogued. Clomiphene is the right call when one of the conditionals below applies.
- → If your priority is wakefulness, pick Armodafinil.
- → If your priority is focus or working memory, pick Armodafinil.
- → If your priority is hormonal optimization, pick Clomiphene.
- → If your priority is fertility, pick Clomiphene.
Edge case: Clomiphene is contraindicated in pregnancy; Armodafinil is the safer pick if that applies.
Default choice: Armodafinil. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Clomiphene only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Armodafinil and Clomiphene?
Armodafinil and Clomiphene differ in category (pharmaceutical vs pharmaceutical), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Armodafinil or Clomiphene?
Armodafinil half-life is 15 hours; Clomiphene half-life is 168 hours.
Can you stack Armodafinil with Clomiphene?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper